Forte Biosciences reports positive Phase 1b vitiligo results for FB102; statistically significant FVASI improvement

Forte Biosciences, Inc.

FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020) vs placebo 7.9% improvement.
Statistically significant improvement observed by day 64 (p=0.023) and continued through week 24 after 12-week treatment.
In subjects with baseline FVASI ≥0.75, FB102 showed 43.2% mean improvement (p=0.006); 58.8% achieved FVASI50, 23.5% FVASI75.
84% (27/32) of FB102-treated subjects improved from baseline to week 24; 0% worsened vs 27% of placebo worsened.
FB102 demonstrated strong safety profile with only mild to moderate AEs, comparing favorably to placebo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.